Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reaffirmed at JMP Securities

JMP Securities reissued their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) in a research note issued to investors on Tuesday, Stock Target Advisor reports. The brokerage currently has a $96.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on ENTA. StockNews.com started coverage on Enanta Pharmaceuticals in a research report on Wednesday, October 12th. They set a hold rating on the stock. Oppenheimer upped their price target on Enanta Pharmaceuticals from $53.00 to $59.00 and gave the company a market perform rating in a research report on Wednesday, August 10th. SVB Leerink upped their price target on Enanta Pharmaceuticals from $44.00 to $50.00 and gave the company a market perform rating in a research report on Monday, August 1st. Finally, Royal Bank of Canada dropped their price target on Enanta Pharmaceuticals from $65.00 to $54.00 and set a sector perform rating on the stock in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $68.71.

Enanta Pharmaceuticals Stock Down 2.1 %

Shares of ENTA opened at $45.44 on Tuesday. The business’s 50 day moving average is $48.33 and its two-hundred day moving average is $51.26. Enanta Pharmaceuticals has a 52-week low of $37.59 and a 52-week high of $92.90. The firm has a market cap of $941.74 million, a price-to-earnings ratio of -7.75 and a beta of 0.53.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last announced its earnings results on Monday, November 21st. The biotechnology company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.10. The company had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative return on equity of 32.42% and a negative net margin of 134.21%. Enanta Pharmaceuticals’s quarterly revenue was down 13.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.22) EPS. On average, equities analysts expect that Enanta Pharmaceuticals will post -6.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC grew its stake in shares of Enanta Pharmaceuticals by 86.7% in the first quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 182 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 660 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Enanta Pharmaceuticals by 164.1% in the second quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 750 shares in the last quarter. Point72 Hong Kong Ltd grew its stake in shares of Enanta Pharmaceuticals by 83.7% in the second quarter. Point72 Hong Kong Ltd now owns 1,565 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 713 shares in the last quarter. Finally, KBC Group NV bought a new position in shares of Enanta Pharmaceuticals in the first quarter worth $113,000. Institutional investors own 97.09% of the company’s stock.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Recommended Stories

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.